Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.

Inventiva S.A.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

DAIX (FRANCE), NEW YORK CITY, (NEW YORK, UNITED STATES), NOVEMBER 21, 2025  INVENTIVA (EURONEXT PARIS AND NASDAQ: IVA) ("INVENTIVA" OR THE "COMPANY"), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF ORAL THERAPIES FOR THE TREATMENT OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS ("MASH"), TODAY REPORTED ITS CASH POSITION AS OF SEPTEMBER 30, 2025 AND ITS REVENUES FOR THE FIRST NINE MONTHS OF 2025.

INVENTIVA REPORTS 2025 THIRD QUARTER FINANCIAL INFORMATION

DAIX (FRANCE), NEW YORK CITY (NEW YORK, UNITED STATES), NOVEMBER 17, 2025  INVENTIVA (EURONEXT PARIS AND NASDAQ: IVA) ("INVENTIVA" OR THE "COMPANY"), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF ORAL THERAPIES FOR THE TREATMENT OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS ("MASH"), TODAY ANNOUNCED THAT THE UNDERWRITERS OF THE PREVIOUSLY ANNOUNCED PUBLIC OFFERING IN THE UNITED STATES (THE "OFFERING") OF 38,961,038 AMERICAN DEPOSITARY SHARES ("ADSS"), EACH REPRESENTING ONE ORDINARY SHARE OF THE COMPANY WITH A NOMINAL VALUE OF 0.01, HAVE EXERCISED IN FULL THEIR OPTION (THE "UNDERWRITERS' OPTION") TO PURCHASE 5,844,155 ADDITIONAL ADSS (THE "ADDITIONAL ADSS"). THE ADDITIONAL ADSS ARE EXPECTED TO BE DELIVERED ON NOVEMBER 18, 2025.

INVENTIVA ANNOUNCES FULL EXERCISE OF UNDERWRITERS' OPTION, BRINGING PROCEEDS OF OFFERING TO APPROXIMATELY $172.5M

DAIX (FRANCE), NEW YORK CITY (NEW YORK, UNITED STATES), NOVEMBER 13, 2025  INVENTIVA (EURONEXT PARIS AND NASDAQ: IVA) ("INVENTIVA" OR THE "COMPANY"), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF ORAL THERAPIES FOR THE TREATMENT OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS ("MASH"), ANNOUNCED THE TRADING RESUMPTION OF ITS ORDINARY SHARES ON THE REGULATED MARKET OF EURONEXT IN PARIS AS FROM 4:30 P.M. (CET).

INVENTIVA ANNOUNCES TRADING RESUMPTION OF ITS ORDINARY SHARES ON EURONEXT PARIS

DAIX (FRANCE), NEW YORK CITY (NEW YORK, UNITED STATES), NOVEMBER 13, 2025  INVENTIVA (EURONEXT PARIS AND NASDAQ: IVA) ("INVENTIVA" OR THE "COMPANY"), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF ORAL THERAPIES FOR THE TREATMENT OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS ("MASH"), TODAY ANNOUNCED THE PRICING OF ITS PREVIOUSLY ANNOUNCED UNDERWRITTEN PUBLIC OFFERING, IN THE UNITED STATES ONLY, OF 38,961,038 NEW AMERICAN DEPOSITARY SHARES ("ADSS"), EACH REPRESENTING ONE NEW ORDINARY SHARE OF THE COMPANY WITH A NOMINAL VALUE OF 0.01, AT AN OFFERING PRICE OF $3.85 PER ADS (THE "OFFERING"). SETTLEMENT AND DELIVERY OF THE OFFERING IS EXPECTED ON NOVEMBER 17, 2025, SUBJECT TO THE SATISFACTION OF CUSTOMARY CLOSING CONDITIONS.

INVENTIVA ANNOUNCES PRICING OF UPSIZED PUBLIC OFFERING OF APPROXIMATELY $150M OF AMERICAN DEPOSITARY SHARES

DAIX (FRANCE), NEW YORK CITY (NEW YORK, UNITED STATES), NOVEMBER 13, 2025  INVENTIVA (EURONEXT PARIS AND NASDAQ: IVA) ("INVENTIVA" OR THE "COMPANY"), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF ORAL THERAPIES FOR THE TREATMENT OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS ("MASH"), ANNOUNCED TODAY THAT TRADING OF ITS ORDINARY SHARES ON THE REGULATED MARKET OF EURONEXT PARIS ("EURONEXT PARIS") WILL BE TEMPORARILY HALTED, AT THE COMPANY'S REQUEST, FROM THE OPENING OF THE MARKET AT 9:00 A.M. (CET). THIS TRADING HALT TAKES PLACE IN THE CONTEXT OF THE PREVIOUSLY ANNOUNCED PUBLIC OFFERING BY THE COMPANY IN THE UNITED STATES ONLY OF NEW AMERICAN DEPOSITARY SHARES (THE "ADSS"), EACH REPRESENTING ONE NEW ORDINARY SHARE OF THE COMPANY WITH A NOMINAL VALUE OF 0.01 (THE "OFFERING"), IN ORDER TO ALLOW FOR THE CONFIRMATION OF ALLOCATIONS TO INVESTORS AND THE ANNOUNCEMENT OF THE PRICING OF THE OFFERING.

INVENTIVA ANNOUNCES TEMPORARY TRADING HALT OF ITS ORDINARY SHARES ON EURONEXT PARIS

DAIX (FRANCE), NEW YORK CITY (NEW YORK, UNITED STATES), NOVEMBER 12, 2025  INVENTIVA (EURONEXT PARIS AND NASDAQ: IVA) ("INVENTIVA" OR THE "COMPANY"), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF ORAL THERAPIES FOR THE TREATMENT OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS ("MASH"), TODAY ANNOUNCED THAT IT PLANS TO OFFER AND SELL APPROXIMATIVELY $125 MILLION (REPRESENTING APPROXIMATELY 108 MILLION) OF NEW AMERICAN DEPOSITARY SHARES ("ADSS") EACH REPRESENTING ONE NEW ORDINARY SHARE OF THE COMPANY WITH A NOMINAL VALUE OF 0.01, IN AN UNDERWRITTEN PUBLIC OFFERING IN THE UNITED STATES ONLY (THE "OFFERING"). THE COMPANY'S ADSS ARE LISTED ON THE NASDAQ GLOBAL MARKET UNDER THE TICKER SYMBOL "IVA" AND THE COMPANY'S ORDINARY SHARES ARE LISTED ON THE REGULATED MARKET OF EURONEXT IN PARIS ("EURONEXT") UNDER THE SYMBOL "IVA". ALL SECURITIES TO BE SOLD IN THE OFFERING WILL BE OFFERED SOLELY BY THE COMPANY.

INVENTIVA ANNOUNCES LAUNCH OF PUBLIC OFFERING

DAIX (FRANCE), NEW YORK CITY (NEW YORK, UNITED STATES), OCTOBER 14, 2025  INVENTIVA (EURONEXT PARIS AND NASDAQ : IVA) (INVENTIVA OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF ORAL THERAPIES FOR THE TREATMENT OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) HAS FILED TODAY A SHELF REGISTRATION STATEMENT ON FORM F-3 (THE REGISTRATION STATEMENT) WITH THE SECURITIES AND EXCHANGE COMMISSION (SEC). THE REGISTRATION STATEMENT INCLUDES A BASE PROSPECTUS AND A SALES AGREEMENT PROSPECTUS FOR A NEW AT-THE-MARKET (ATM) PROGRAM, AND ALLOWS THE COMPANY TO ISSUE AND SELL, FROM TIME TO TIME, "AT-THE-MARKET", INCLUDING TO UNSOLICITED INVESTORS WHO HAVE EXPRESSED AN INTEREST, ORDINARY SHARES IN THE FORM OF AMERICAN DEPOSITARY SHARES (ADS). EACH ADS REPRESENTS ONE ORDINARY SHARE OF INVENTIVA, FOR AGGREGATE GROSS SALES PROCEEDS OF UP TO $100 MILLION (SUBJECT TO A REGULATORY LIMIT OF 30% DILUTION OVER A ROLLING PERIOD OF 12 MONTHS AND WITHIN THE LIMITS OF INVESTORS' REQUESTS EXPRESSED IN THE CONTEXT OF THE PROGRAM), PURSUANT TO THE TERMS OF A NEW SALES AGREEMENT ENTERED INTO WITH PIPER SANDLER & CO. (PIPER SANDLER), ACTING AS SALES AGENT.

INVENTIVA ANNOUNCES THE IMPLEMENTATION OF A NEW ATM PROGRAM

PRESENTATION OF A COMPARISON BETWEEN DIGITAL AND GLASS SLIDE HISTOLOGY FROM SCREENING BIOPSIES IN THE PHASE 3 NATIV3 STUDY PRESENTATION OF DIGITAL PATHOLOGY DATA FROM PRECLINICAL STUDIES WITH LANIFIBRANOR DAIX (FRANCE), NEW YORK CITY (NEW YORK, UNITED STATES), OCTOBER 7, 2025 - INVENTIVA (EURONEXT PARIS AND NASDAQ: IVA) ("INVENTIVA" OR THE "COMPANY"), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF ORAL THERAPIES FOR THE TREATMENT OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS ("MASH"), TODAY ANNOUNCED FOUR ABSTRACTS PRESENTATIONS AT THE UPCOMING ANNUAL AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASES (AASLD) THE LIVER MEETING 2025 BEING HELD NOVEMBER 7 TO 11, 2025 IN WASHINGTON, DC.

INVENTIVA TO PRESENT MULTIPLE ABSTRACTS AT AASLD THE LIVER MEETING 2025

DAIX (FRANCE), NEW YORK CITY (NEW YORK, UNITED STATES), OCTOBER 1, 2025 INVENTIVA (EURONEXT PARIS AND NASDAQ: IVA) (INVENTIVA OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF ORAL THERAPIES FOR THE TREATMENT OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH), TODAY ANNOUNCED THE APPOINTMENT OF ANDREW OBENSHAIN AS CHIEF EXECUTIVE OFFICER (CEO) OF THE COMPANY. MR. OBENSHAIN WILL ALSO JOIN THE COMPANY'S BOARD OF DIRECTORS. HE SUCCEEDS FRDRIC CREN, THE COMPANY'S CO-FOUNDER, WHO HAS SERVED AS CEO SINCE ITS INCEPTION IN 2012. MR. CREN IS ALSO STEPPING DOWN FROM THE BOARD OF DIRECTORS AND WILL WORK WITH MR. OBENSHAIN TO ENSURE A SMOOTH TRANSITION AND CONTINUITY IN THE COMPANY'S STRATEGIC PRIORITIES.

INVENTIVA APPOINTS ANDREW OBENSHAIN AS CHIEF EXECUTIVE OFFICER

DAIX (FRANCE), NEW YORK CITY (NEW YORK, UNITED STATES), SEPTEMBER 29, 2025  INVENTIVA (EURONEXT PARIS AND NASDAQ: IVA) (INVENTIVA OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF ORAL THERAPIES FOR THE TREATMENT OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH), TODAY REPORTED ITS FINANCIAL RESULTS FOR THE SIX MONTHS ENDED JUNE 30, 2025, AND PROVIDED A CORPORATE UPDATE. FRDRIC CREN, CHIEF EXECUTIVE OFFICER AND COFOUNDER OF INVENTIVA, STATED:  THE FIRST HALF OF 2025 HAS BEEN A DEFINING PERIOD FOR INVENTIVA, WITH DECISIVE PROGRESS ACROSS BOTH OUR CLINICAL PROGRAM AND OUR FINANCIAL POSITION. AS WE ADVANCE INTO THE FINAL STRETCH OF OUR PHASE 3 CLINICAL TRIAL IN MASH, WE ARE REINFORCING OUR ORGANIZATION TO PREPARE FOR THE UPCOMING DATA READOUTS AND POTENTIAL REGULATORY SUBMISSIONS. FINANCIALLY, WE REINFORCED OUR POSITION WITH THE CLOSING OF THE 116 MILLION SECOND TRANCHE OF THE STRUCTURED FINANCING ANNOUNCED IN OCTOBER 2024, UNLOCKED BY THE RANDOMIZATION OF THE LAST PATIENT IN THE MAIN COHORT OF THE NATIV3 STUDY, A CRITICAL MILESTONE IN OUR JOURNEY. INVENTIVA HAS ENTERED THE SECOND HALF OF THE YEAR WITH CONFIDENCE AND UNDIMINISHED AMBITION: TO TURN THE HOPE OF MILLIONS OF PATIENTS LIVING WITH MASH INTO THERAPEUTIC REALITY. 

Inventiva S.A.

IVA

Price

Financial Reports

No items found.

Press Releases

Inventiva S.A.

IVA.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

IVA